Suvretta Capital Management Boosts Stake in Compass Therapeutics

Institutional investor increases ownership in biotech company by 97.2% in Q3

Mar. 14, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Suvretta Capital Management LLC, an institutional investor, boosted its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 97.2% in the third quarter of 2025, according to a recent SEC filing. The firm now owns approximately 10.2% of the biotech company's outstanding shares.

Why it matters

Compass Therapeutics is a clinical-stage biotech company focused on developing novel immuno-oncology therapies. Institutional investors like Suvretta Capital Management taking larger positions in the company signals confidence in its pipeline and future growth potential.

The details

According to the filing, Suvretta Capital Management increased its position in Compass Therapeutics by adding 6,951,666 shares in the third quarter. The firm now holds a total of 14,101,159 shares, worth approximately $49.4 million based on the stock's closing price at the end of the quarter.

  • Suvretta Capital Management increased its stake in Compass Therapeutics during the third quarter of 2025.

The players

Suvretta Capital Management LLC

An institutional investment management firm that focuses on long-term investments in public equities.

Compass Therapeutics, Inc.

A clinical-stage biotechnology company developing novel immuno-oncology therapies, including bispecific antibodies and checkpoint modulators.

Got photos? Submit your photos here. ›

The takeaway

Suvretta Capital Management's increased stake in Compass Therapeutics suggests the firm sees significant growth potential in the biotech company's pipeline of innovative cancer treatments. This investment could signal broader institutional confidence in Compass Therapeutics' future prospects.